十二个中低收入国家医护人员对流感疫苗的接受度与推荐意愿:2018至2020年汇总分析
该研究汇总了2018至2020年12个中低收入国家针对医护人员流感疫苗知识、态度与实践的横断面调查个体数据,共纳入10281名医护人员。结果显示74%的医护人员若疫苗免费则愿意接种,85%会向患者推荐疫苗,且自身愿意接种者推荐疫苗的可能性约为不愿意者的3倍(OR 3.1,95%CI 1.8-5.2)。
要点
- 74%(6341名)医护人员表示若疫苗免费提供则愿意接种。
- 85%的医护人员会向患者推荐疫苗。
- 自身愿意接种疫苗者向患者推荐疫苗的可能性约为不愿意者的3倍(OR 3.1,95%CI 1.8-5.2)。
核心结论
- 提高医护人员流感疫苗覆盖率可通过增加医护人员向患者推荐疫苗的可能性来放大疫苗接种的正面影响。
- 提高疫苗覆盖率的成功策略包括卫生行政部门的明确指导、基于行为改变模型的干预措施以及免费获得疫苗。
研究设计与样本
- 研究汇总了2018至2020年12个中低收入国家(阿尔巴尼亚、亚美尼亚、科特迪瓦、肯尼亚、吉尔吉斯斯坦、老挝、黎巴嫩、摩洛哥、北马其顿、突尼斯、塔吉克斯坦和乌干达)针对医护人员流感疫苗的横断面调查个体数据。
- 其中11个国家采用基于健康信念模型的标准方案和问卷,测量对流感疾病易感性和严重性的认知、疫苗接种的益处、障碍和激励因素。
- 分析按是否存在国家流感疫苗接种规划分组,并调整地理区域。
- 分析纳入来自12个国家的10281名医护人员,覆盖世界卫生组织六个区域中的四个:非洲区、东地中海区、欧洲区和西太平洋区。
- 样本分布为低收入国家3183人(31%)、中低收入国家4744人(46%)、中高收入国家2354人(23%)。
主要发现
- 纳入分析的国家中,半数(50%)报告在数据收集当年和前一年医护人员使用了季节性流感疫苗,其余国家没有针对医护人员的流感疫苗接种规划。
- 74%(6341名)医护人员报告若疫苗免费提供则愿意接种。
- 低收入国家医护人员愿意为季节性流感疫苗支付的价格占其国家年人均卫生支出的比例(6.26%,IQR 3.13-12.52)高于中低收入国家和中高收入国家的医护人员。
- 无季节性流感疫苗接种规划国家的医护人员愿意支付的价格比例(5.01%,IQR 2.24-8.34)高于有接种规划国家的医护人员。
- 85%的医护人员会向患者推荐疫苗;自身愿意接种疫苗者向患者推荐疫苗的可能性约为不愿意者的3倍(OR 3.1,95%CI 1.8-5.2)。
临床怎么用
- 作者认为,提高医护人员季节性流感疫苗覆盖率可放大疫苗接种的正面影响,因为这会增加医护人员向患者推荐疫苗的可能性。
- 作者指出,提高疫苗覆盖率的成功策略包括卫生行政部门的明确指导、基于行为改变模型的干预措施以及免费获得疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although healthcare personnel (HCP) are targeted for influenza vaccination they typically underutilize vaccines especially in low- and middle-income countries. We explored knowledge, attitudes, and practices of HCP about seasonal influenza vaccines (SIV) to identify factors associated with and modifiable barriers to SIV uptake. METHODS: We pooled individual-level data from cross-sectional surveys about SIV conducted among health workers in 12 low- and middle- income countries during 2018-2020 (i.e., Albania, Armenia, Cote d'Ivoire, Kenya, Kyrgyzstan, Lao PDR, Lebanon, Morocco, North Macedonia, Tunisia, Tajikistan, and Uganda). Eleven countries used a standard protocol and questionnaire based on the Health Belief Model to measure perceptions of susceptibility and severity of influenza disease, benefits of, barriers to, and motivators for vaccination. We analyzed attitudes and perceptions among HCP, including acceptance of vaccine for themselves and willingness to recommend vaccines to patients, grouped by the presence/absence of a national influenza vaccination program. Models were adjusted for geographic region. RESULTS: Our analysis included 10,281 HCP from 12 countries representing four of the six World Health Organization regions: African, Eastern Mediterranean, European, and Western Pacific. The sample was distributed across low income (LIC) (3,183, 31 %), lower-middle (LMIC) (4,744, 46 %), and upper-middle income (UMIC) (2,354, 23 %) countries. Half (50 %) of the countries included in the analysis reported SIV use among HCP in both the year of and the year preceding data collection while the remainder had no influenza vaccination program for HCP. Seventy-four percent (6,341) of HCP reported that they would be willing to be vaccinated if the vaccine was provided free of charge. HCP in LICs were willing to pay prices for SIV representing a higher percentage of their country's annual health expenditure per capita (6.26 % [interquartile range, IQR: 3.13-12.52]) compared to HCP in LMICs and UMICs. HCP in countries with no SIV program were also willing to pay a higher percentage for SIV (5.01 % [IQR: 2.24-8.34]) compared to HCP in countries with SIV programs.. Most (85 %) HCP in our analysis would recommend vaccines to their patients, and those who would accept vaccines for themselves were 3 times more likely to recommend vaccines to their patients (OR 3.1 [95 % CI 1·8, 5·2]). CONCLUSION: Increasing uptake of SIV among HCP can amplify positive impacts of vaccination by increasing the likelihood that HCP recommend vaccines to their patients. Successful strategies to achieve increased uptake of vaccines include clear guidance from health authorities, interventions based on behavior change models, and access to vaccine free-of-charge.
引用
- McCarron M, Marcenac P, Yau TS, et al. Healthcare personnel acceptance and recommendations for influenza vaccine in twelve low- and middle-income countries: A pooled analysis from 2018 to 2020. Vaccine. 2024. PMID: 39198045. doi:10.1016/j.vaccine.2024.01.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。